3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Dermatologic
1
Conditions
Neoplasms
7
Multiple Myeloma
7
Lymphoma
7
Carcinoma, Non-Small-Cell Lung
6
Lymphoma, T-Cell, Cutaneous
4
Mycosis Fungoides
3
Sezary Syndrome
2
Recurrence
2
Lymphoproliferative Disorders
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Large B-Cell, Diffuse
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Vascular Diseases
1
Stage IIIB or IV Non-Small Cell Lung Cancer
1
Paraproteinemias
1
Pancreatic Neoplasms
1
Neuroectodermal Tumors
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms by Histologic Type
1
Myelodysplastic Syndromes
1
Mesothelioma
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, B-Cell
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Interventions
Rituximab
8
dacetuzumab
5
blinatumomab
5
ibrutinib
3
Cyclophosphamide
3
tetulomab tetraxetan lu-177
2
ponatinib
2
cobomarsen
2
acalabrutinib
2
Vincristine
2
Prednisone
2
Lutetium
2
Ifosfamide
2
Everolimus
2
Etoposide
2
Doxorubicin
2
Carboplatin
2
venetoclax
1
sepantronium
1
pomalidomide
1
obinutuzumab
1
fludarabine
1
ficlatuzumab
1
enzalutamide
1
durvalumab
1
denileukin diftitox
1
cirmtuzumab
1
amonafide
1
Vorinostat
1
Tinzaparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Lymphatic Diseases
×
Vorinostat
×
Clear all
NCT03713320
2022-04-08
SOLAR
miRagen Therapeutics, Inc.
Phase 2
Terminated
37 enrolled
23 charts